Orthofix Medical Inc.
OFIX | NASDAQ
$8.95
+$0.24 (+2.76%)
At close: Sep 21, 2026, 4:00 PM ET
$9.02
+$0.07 (+0.82%)
Pre-market:
Sep 22, 2026, 4:42 AM ET
Company Profile
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Key Executives
| Name | Position |
|---|---|
| Massimo Calafiore | President, Chief Executive Officer & Director |
| J. Andres Cedron | Chief Legal Officer & Corporate Secretary |
| Julie Andrews | Chief Financial Officer |
| Aviva McPherron | President of Global Operations & Quality |
| Beau Standish | Chief Enabling Technologies Officer |
| Geoffrey C. Gillespie | Chief Accounting Officer |
| Jill Mason | Chief Compliance & Risk Officer |
| Julie D. Dewey | Chief Investor Relations & Communications Officer |
| Patrick Fisher | President of Global Biologics & Limb Reconstruction |
| Stephanie Walsh | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | S-8 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
Orthofix Medical Inc.
| Country | United States |
| IPO Date | Apr 23, 1992 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Massimo Calafiore |
Contact Details
3451 Plano Parkway Lewisville,
Texas 75056 United States
Stock Details
| Ticker Symbol | OFIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000884624 |
| CUSIP Number | 68752M108 |
| ISIN Number | US68752M1080 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove OFIX